Shopping Cart 0
Cart Subtotal
USD 0

Advanced Accelerator Applications SA - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 750

Details

Summary

Advanced Accelerator Applications SA (AAA), a Novartis company, is engaged in developing, producing and commercializing diagnostic and therapeutic molecular nuclear medicine products. The company's lead product candidate comprises Lutathera, NETSPOT, SOMAKIT TOC, Gluscan, Gluscan 500, Barnascan, Fluorochol, AAACholine, Cholscan, MIBITEC, Adamibi, Leukokit, Neurolite and Lumark. AAA develops new medicines which targets the orphan diseases in the field of cardiology, oncology, neurology and inflammation. It is also engaged in manufacturing Positron Emission tomography (PET) and single-photon emission computed tomography (SPECT). The company operates in France, Italy, the UK, Germany, Switzerland, Spain, Poland, Portugal, Israel, the US, and Canada, among others. AAA is headquartered in Saint-Genis-Pouilly, Auvergne, France.

Advanced Accelerator Applications SA-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Advanced Accelerator Applications SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Advanced Accelerator Applications SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Advanced Accelerator Applications SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Advanced Accelerator Applications SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Advanced Accelerator Applications SA, Medical Devices Deals, 2012 to YTD 2018 10

Advanced Accelerator Applications SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Advanced Accelerator Applications SA, Pharmaceuticals & Healthcare, Deal Details 13

Venture Financing 13

Advanced Accelerator Applications Raises USD26 Million in Venture Financing 13

Advanced Accelerator Applications Raises USD 56 Million In Venture Financing 14

Advanced Accelerator Raises USD 6 Million In First Tranche Of Venture Financing 15

Partnerships 16

Advanced Accelerator Applications Enters into Agreement with National Cancer Institute 16

Vect-Horus Enters into Collaboration Agreement with Advanced Accelerator Applications for Radio-Imaging Agents 17

Licensing Agreements 18

Advanced Accelerator Enters into Licensing Agreement with Cancer Targeted Technology 18

Advanced Accelerator Applications Enters into Licensing Agreement with Erasmus University Medical Center and Demokritos National Center 19

Advanced Accelerator Applications Enters into Licensing Agreement with Johns Hopkins University 20

Fujifilm RI Pharma Enters into Licensing Agreement with Advanced Accelerator Applications 21

Equity Offering 22

Advanced Accelerator Applications Prices Public Offering of American Depositary Shares for USD172.5 Million 22

Advanced Accelerator Applications to Raise up to USD80 Million in IPO 24

Acquisition 26

Novartis Acquires Advanced Accelerator Applications for USD3.9 Billion 26

Advanced Accelerator Applications Acquires IDB Group 28

Advanced Accelerator Applications Acquires Remaining 49.9% Stake in Atreus Pharma 29

Advanced Accelerator Applications SA-Key Competitors 30

Advanced Accelerator Applications SA-Key Employees 31

Advanced Accelerator Applications SA-Locations And Subsidiaries 32

Head Office 32

Other Locations & Subsidiaries 32

Recent Developments 34

Financial Announcements 34

Nov 17, 2017: Advanced Accelerator Applications Reports 39% Sales Growth for Third Quarter 2017 34

Aug 31, 2017: Advanced Accelerator Applications Reports 32% Sales Growth for Second Quarter 2017 35

May 31, 2017: Advanced Accelerator Applications Reports 21% Sales Growth for First Quarter 2017 37

Mar 23, 2017: Advanced Accelerator Applications Reports 23% Sales Growth for Fiscal 2016; Continued NETSPOT Launch Success 39

Corporate Communications 41

May 25, 2017: Advanced Accelerator Applications Appoints Christine Mikail to Board of Directors 41

Product News 42

09/29/2017: Advanced Accelerator Applications Announces European Approval of Lutetium (177Lu) Oxodotreotide (Lutathera) for Gastroenteropancreatic Neuroendocrine (GEP-NET) Tumors 42

07/28/2017: EMA Recommends Granting a Marketing Authorisation for Lutetium (177Lu) Oxodotreotide 43

07/21/2017: Advanced Accelerator Applications Announces Positive CHMP Opinion Recommending Approval of Lutetium 177Lu Oxodotreotide (Lutathera) for Gastroenteropancreatic Neuroendocrine (GEP-NET) Tumors 44

03/21/2018: Lenox Hill successfully treats esthesioneuroblastoma with PRRT 45

01/26/2018: Lutathera Drug Approved for Pancreatic Neuroendocrine Tumors 46

01/26/2018: Advanced Accelerator Applications Receives FDA Approval for Lutathera for Treatment of Gastroenteropancreatic Neuroendocrine Tumors 47

Product Approvals 48

Aug 28, 2017: Advanced Accelerator Applications Announces New Prescription Drug User Fee Act date of January 26, 2018, for Lutetium Lu 177 Dotatate (Lutathera) 48

Jul 27, 2017: Advanced Accelerator Applications Completes Resubmission of NDA for Lutetium Lu 177 Dotatate (Lutathera) to FDA 49

Jan 09, 2017: Advanced Accelerator Applications CEO Provides Progress Report on Corporate Developments of 2016; Asserts Confidence in Ability to Address FDA Comments on Lutathera NDA 50

Clinical Trials 52

Jun 12, 2018: Newly-Approved Therapy Provides Improved Quality of Life for Patients with Advanced Metastatic Midgut Neuroendocrine Tumors 52

Jun 07, 2018: Novartis announces JCO publication of Lutathera NETTER-1 data showing significantly longer time to deterioration of key quality of life measures in patients with progressive midgut NETs 53

Feb 21, 2018: New Cancer Treatment for Neuroendocrine Tumors 54

Sep 06, 2017: Advanced Accelerator Applications Announce First Patient in Bridging Study in Japan for Lutetium Lu 177 Dotatate (Lutathera) 55

Jun 12, 2017: Targeted Radionuclide Treatment for Neuroendocrine Tumors Improves Quality of Life 56

Mar 06, 2017: Advanced Accelerator Applications Announces Presentation of Quality of Life Findings from NETTER-1 Phase III Study at ENETS 57

Jan 12, 2017: Advanced Accelerator Applications Announces New England Journal of Medicine Publication of Lutathera NETTER-1 Phase III Results 58

Jan 12, 2017: New drug in development shows improved survival for patients with advanced metastat 59

Other Significant Developments 60

Jan 09, 2017: Advanced Accelerator Applications CEO Provides Progress Report on Corporate Developments of 2016; Asserts Confidence in Ability to Address FDA Comments on Lutathera NDA 60

Appendix 62

Methodology 62

About GlobalData 62

Contact Us 62

Disclaimer 62


List Of Figure

List of Figures

Advanced Accelerator Applications SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Advanced Accelerator Applications SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Advanced Accelerator Applications SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Advanced Accelerator Applications SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Advanced Accelerator Applications SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Advanced Accelerator Applications SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Advanced Accelerator Applications SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Advanced Accelerator Applications SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Advanced Accelerator Applications SA, Medical Devices Deals, 2012 to YTD 2018 10


List Of Table

List of Tables

Advanced Accelerator Applications SA, Pharmaceuticals & Healthcare, Key Facts 2

Advanced Accelerator Applications SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Advanced Accelerator Applications SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Advanced Accelerator Applications SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Advanced Accelerator Applications SA, Deals By Therapy Area, 2012 to YTD 2018 9

Advanced Accelerator Applications SA, Medical Devices Deals, 2012 to YTD 2018 10

Advanced Accelerator Applications SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Advanced Accelerator Applications Raises USD26 Million in Venture Financing 13

Advanced Accelerator Applications Raises USD 56 Million In Venture Financing 14

Advanced Accelerator Raises USD 6 Million In First Tranche Of Venture Financing 15

Advanced Accelerator Applications Enters into Agreement with National Cancer Institute 16

Vect-Horus Enters into Collaboration Agreement with Advanced Accelerator Applications for Radio-Imaging Agents 17

Advanced Accelerator Enters into Licensing Agreement with Cancer Targeted Technology 18

Advanced Accelerator Applications Enters into Licensing Agreement with Erasmus University Medical Center and Demokritos National Center 19

Advanced Accelerator Applications Enters into Licensing Agreement with Johns Hopkins University 20

Fujifilm RI Pharma Enters into Licensing Agreement with Advanced Accelerator Applications 21

Advanced Accelerator Applications Prices Public Offering of American Depositary Shares for USD172.5 Million 22

Advanced Accelerator Applications to Raise up to USD80 Million in IPO 24

Novartis Acquires Advanced Accelerator Applications for USD3.9 Billion 26

Advanced Accelerator Applications Acquires IDB Group 28

Advanced Accelerator Applications Acquires Remaining 49.9% Stake in Atreus Pharma 29

Advanced Accelerator Applications SA, Key Competitors 30

Advanced Accelerator Applications SA, Key Employees 31

Advanced Accelerator Applications SA, Subsidiaries 32

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Advanced Accelerator Applications SA, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

Advanced Accelerator Applications SA (AAA), a Novartis company, is engaged in developing, producing and commercializing diagnostic and therapeutic molecular nuclear medicine products. The company's lead product candidate comprises Lutathera, NETSPOT, SOMAKIT TOC, Gluscan, Gluscan 500, Barnascan, Fluorochol, AAACholine, Cholscan, MIBITEC, Adamibi, Leukokit, Neurolite and Lumark. AAA develops new medicines which targets the orphan diseases in the field of cardiology, oncology, neurology and inflammation. It is also engaged in manufacturing Positron Emission tomography (PET) and single-photon emission computed tomography (SPECT). The company operates in France, Italy, the UK, Germany, Switzerland, Spain, Poland, Portugal, Israel, the US, and Canada, among others. AAA is headquartered in Saint-Genis-Pouilly, Auvergne, France.

Advanced Accelerator Applications SA-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Advanced Accelerator Applications SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Advanced Accelerator Applications SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Advanced Accelerator Applications SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Advanced Accelerator Applications SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Advanced Accelerator Applications SA, Medical Devices Deals, 2012 to YTD 2018 10

Advanced Accelerator Applications SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Advanced Accelerator Applications SA, Pharmaceuticals & Healthcare, Deal Details 13

Venture Financing 13

Advanced Accelerator Applications Raises USD26 Million in Venture Financing 13

Advanced Accelerator Applications Raises USD 56 Million In Venture Financing 14

Advanced Accelerator Raises USD 6 Million In First Tranche Of Venture Financing 15

Partnerships 16

Advanced Accelerator Applications Enters into Agreement with National Cancer Institute 16

Vect-Horus Enters into Collaboration Agreement with Advanced Accelerator Applications for Radio-Imaging Agents 17

Licensing Agreements 18

Advanced Accelerator Enters into Licensing Agreement with Cancer Targeted Technology 18

Advanced Accelerator Applications Enters into Licensing Agreement with Erasmus University Medical Center and Demokritos National Center 19

Advanced Accelerator Applications Enters into Licensing Agreement with Johns Hopkins University 20

Fujifilm RI Pharma Enters into Licensing Agreement with Advanced Accelerator Applications 21

Equity Offering 22

Advanced Accelerator Applications Prices Public Offering of American Depositary Shares for USD172.5 Million 22

Advanced Accelerator Applications to Raise up to USD80 Million in IPO 24

Acquisition 26

Novartis Acquires Advanced Accelerator Applications for USD3.9 Billion 26

Advanced Accelerator Applications Acquires IDB Group 28

Advanced Accelerator Applications Acquires Remaining 49.9% Stake in Atreus Pharma 29

Advanced Accelerator Applications SA-Key Competitors 30

Advanced Accelerator Applications SA-Key Employees 31

Advanced Accelerator Applications SA-Locations And Subsidiaries 32

Head Office 32

Other Locations & Subsidiaries 32

Recent Developments 34

Financial Announcements 34

Nov 17, 2017: Advanced Accelerator Applications Reports 39% Sales Growth for Third Quarter 2017 34

Aug 31, 2017: Advanced Accelerator Applications Reports 32% Sales Growth for Second Quarter 2017 35

May 31, 2017: Advanced Accelerator Applications Reports 21% Sales Growth for First Quarter 2017 37

Mar 23, 2017: Advanced Accelerator Applications Reports 23% Sales Growth for Fiscal 2016; Continued NETSPOT Launch Success 39

Corporate Communications 41

May 25, 2017: Advanced Accelerator Applications Appoints Christine Mikail to Board of Directors 41

Product News 42

09/29/2017: Advanced Accelerator Applications Announces European Approval of Lutetium (177Lu) Oxodotreotide (Lutathera) for Gastroenteropancreatic Neuroendocrine (GEP-NET) Tumors 42

07/28/2017: EMA Recommends Granting a Marketing Authorisation for Lutetium (177Lu) Oxodotreotide 43

07/21/2017: Advanced Accelerator Applications Announces Positive CHMP Opinion Recommending Approval of Lutetium 177Lu Oxodotreotide (Lutathera) for Gastroenteropancreatic Neuroendocrine (GEP-NET) Tumors 44

03/21/2018: Lenox Hill successfully treats esthesioneuroblastoma with PRRT 45

01/26/2018: Lutathera Drug Approved for Pancreatic Neuroendocrine Tumors 46

01/26/2018: Advanced Accelerator Applications Receives FDA Approval for Lutathera for Treatment of Gastroenteropancreatic Neuroendocrine Tumors 47

Product Approvals 48

Aug 28, 2017: Advanced Accelerator Applications Announces New Prescription Drug User Fee Act date of January 26, 2018, for Lutetium Lu 177 Dotatate (Lutathera) 48

Jul 27, 2017: Advanced Accelerator Applications Completes Resubmission of NDA for Lutetium Lu 177 Dotatate (Lutathera) to FDA 49

Jan 09, 2017: Advanced Accelerator Applications CEO Provides Progress Report on Corporate Developments of 2016; Asserts Confidence in Ability to Address FDA Comments on Lutathera NDA 50

Clinical Trials 52

Jun 12, 2018: Newly-Approved Therapy Provides Improved Quality of Life for Patients with Advanced Metastatic Midgut Neuroendocrine Tumors 52

Jun 07, 2018: Novartis announces JCO publication of Lutathera NETTER-1 data showing significantly longer time to deterioration of key quality of life measures in patients with progressive midgut NETs 53

Feb 21, 2018: New Cancer Treatment for Neuroendocrine Tumors 54

Sep 06, 2017: Advanced Accelerator Applications Announce First Patient in Bridging Study in Japan for Lutetium Lu 177 Dotatate (Lutathera) 55

Jun 12, 2017: Targeted Radionuclide Treatment for Neuroendocrine Tumors Improves Quality of Life 56

Mar 06, 2017: Advanced Accelerator Applications Announces Presentation of Quality of Life Findings from NETTER-1 Phase III Study at ENETS 57

Jan 12, 2017: Advanced Accelerator Applications Announces New England Journal of Medicine Publication of Lutathera NETTER-1 Phase III Results 58

Jan 12, 2017: New drug in development shows improved survival for patients with advanced metastat 59

Other Significant Developments 60

Jan 09, 2017: Advanced Accelerator Applications CEO Provides Progress Report on Corporate Developments of 2016; Asserts Confidence in Ability to Address FDA Comments on Lutathera NDA 60

Appendix 62

Methodology 62

About GlobalData 62

Contact Us 62

Disclaimer 62


List Of Figure

List of Figures

Advanced Accelerator Applications SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Advanced Accelerator Applications SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Advanced Accelerator Applications SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Advanced Accelerator Applications SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Advanced Accelerator Applications SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Advanced Accelerator Applications SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Advanced Accelerator Applications SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Advanced Accelerator Applications SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Advanced Accelerator Applications SA, Medical Devices Deals, 2012 to YTD 2018 10


List Of Table

List of Tables

Advanced Accelerator Applications SA, Pharmaceuticals & Healthcare, Key Facts 2

Advanced Accelerator Applications SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Advanced Accelerator Applications SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Advanced Accelerator Applications SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Advanced Accelerator Applications SA, Deals By Therapy Area, 2012 to YTD 2018 9

Advanced Accelerator Applications SA, Medical Devices Deals, 2012 to YTD 2018 10

Advanced Accelerator Applications SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Advanced Accelerator Applications Raises USD26 Million in Venture Financing 13

Advanced Accelerator Applications Raises USD 56 Million In Venture Financing 14

Advanced Accelerator Raises USD 6 Million In First Tranche Of Venture Financing 15

Advanced Accelerator Applications Enters into Agreement with National Cancer Institute 16

Vect-Horus Enters into Collaboration Agreement with Advanced Accelerator Applications for Radio-Imaging Agents 17

Advanced Accelerator Enters into Licensing Agreement with Cancer Targeted Technology 18

Advanced Accelerator Applications Enters into Licensing Agreement with Erasmus University Medical Center and Demokritos National Center 19

Advanced Accelerator Applications Enters into Licensing Agreement with Johns Hopkins University 20

Fujifilm RI Pharma Enters into Licensing Agreement with Advanced Accelerator Applications 21

Advanced Accelerator Applications Prices Public Offering of American Depositary Shares for USD172.5 Million 22

Advanced Accelerator Applications to Raise up to USD80 Million in IPO 24

Novartis Acquires Advanced Accelerator Applications for USD3.9 Billion 26

Advanced Accelerator Applications Acquires IDB Group 28

Advanced Accelerator Applications Acquires Remaining 49.9% Stake in Atreus Pharma 29

Advanced Accelerator Applications SA, Key Competitors 30

Advanced Accelerator Applications SA, Key Employees 31

Advanced Accelerator Applications SA, Subsidiaries 32

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Advanced Accelerator Applications SA, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.